TAIWAN LIPOSOME/S (NASDAQ:TLC)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Thursday, AnalystRatings.com reports. They currently have a $11.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 103.79% from the company’s current price.
A number of other research analysts have also issued reports on TLC. Cantor Fitzgerald dropped their price objective on shares of TAIWAN LIPOSOME/S from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday. ValuEngine upgraded shares of TAIWAN LIPOSOME/S from a “hold” rating to a “buy” rating in a report on Tuesday, December 31st. Finally, Zacks Investment Research lowered shares of TAIWAN LIPOSOME/S from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $9.00.
Shares of NASDAQ TLC opened at $5.40 on Thursday. The company has a 50 day simple moving average of $5.38 and a 200 day simple moving average of $5.23. The firm has a market cap of $200.24 million, a PE ratio of -9.64 and a beta of 0.78. TAIWAN LIPOSOME/S has a 1 year low of $4.61 and a 1 year high of $8.54. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.01 and a quick ratio of 2.01.
About TAIWAN LIPOSOME/S
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
Recommended Story: Balanced Fund
Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.